Martin Fan
Stock Analyst at Wedbush
(4.73)
# 138
Out of 5,139 analysts
18
Total ratings
76.47%
Success rate
48.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORKA Oruka Therapeutics | Maintains: Outperform | $42 → $45 | $33.40 | +34.73% | 2 | Jan 13, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Outperform | $45 | $20.16 | +123.21% | 3 | Dec 22, 2025 | |
| VOR Vor Biopharma | Assumes: Neutral | $9 | $15.75 | -42.86% | 1 | Nov 25, 2025 | |
| IMA ImageneBio | Assumes: Underperform | $2 | $6.53 | -69.37% | 1 | Nov 25, 2025 | |
| ANAB AnaptysBio | Reiterates: Outperform | $50 | $45.68 | +9.46% | 5 | Nov 24, 2025 | |
| SANA Sana Biotechnology | Maintains: Outperform | $5 → $6 | $4.58 | +31.00% | 2 | Nov 7, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Outperform | $18 → $23 | $4.42 | +420.36% | 2 | Oct 17, 2025 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $38 | $7.42 | +412.13% | 1 | Jul 9, 2025 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $8 | $2.62 | +205.34% | 1 | May 28, 2025 |
Oruka Therapeutics
Jan 13, 2026
Maintains: Outperform
Price Target: $42 → $45
Current: $33.40
Upside: +34.73%
Zenas BioPharma
Dec 22, 2025
Reiterates: Outperform
Price Target: $45
Current: $20.16
Upside: +123.21%
Vor Biopharma
Nov 25, 2025
Assumes: Neutral
Price Target: $9
Current: $15.75
Upside: -42.86%
ImageneBio
Nov 25, 2025
Assumes: Underperform
Price Target: $2
Current: $6.53
Upside: -69.37%
AnaptysBio
Nov 24, 2025
Reiterates: Outperform
Price Target: $50
Current: $45.68
Upside: +9.46%
Sana Biotechnology
Nov 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $4.58
Upside: +31.00%
Artiva Biotherapeutics
Oct 17, 2025
Maintains: Outperform
Price Target: $18 → $23
Current: $4.42
Upside: +420.36%
Cartesian Therapeutics
Jul 9, 2025
Initiates: Outperform
Price Target: $38
Current: $7.42
Upside: +412.13%
Aclaris Therapeutics
May 28, 2025
Initiates: Outperform
Price Target: $8
Current: $2.62
Upside: +205.34%